Onward Therapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 13

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $27.5M

  • Investors
  • 10

Onward Therapeutics General Information

Description

Operator of an oncology company intended to develop breakthrough medicines for the treatment of cancer. The company provides optimized cell therapy products consisting of highly activated and alloreactive allogeneic natural killer (NK) cells, enhancing tumor selectivity and cell signaling interference, enabling medical professionals to use bispecific antibodies for immuno-oncology to treat cancer patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2F, Number 60, Songjiang Road
  • Zhongshan District
  • Taipei
  • Taiwan
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 2F, Number 60, Songjiang Road
  • Zhongshan District
  • Taipei
  • Taiwan

Onward Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Onward Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series B) 17-Nov-2026 $27.5M Completed Clinical Trials - Phase 1
2. Later Stage VC (Series B1) Cancelled Clinical Trials - Phase 1
1. Later Stage VC (Series A) 02-Aug-2024 $84.8M $84.8M Completed Clinical Trials - Phase 1
To view Onward Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Onward Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Onward Therapeutics Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bailey Biofund Venture Capital Minority
Chlitina Corporation Minority
Everbright Biofund Venture Capital Minority
Grand Fortune Capital (HK) Company Asset Manager Minority
Hercules Bioventure Partners Taiwan Venture Capital Minority
You’re viewing 5 of 10 investors. Get the full list »

Onward Therapeutics Investments & Acquisitions (2)

Onward Therapeutics’s most recent deal was a Merger/Acquisition with EMERCell. The deal was made on 17-Feb-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
EMERCell 17-Feb-2021 Merger/Acquisition Drug Discovery
Biomunex Pharmaceuticals 16-Feb-2021 Later Stage VC Drug Discovery
To view Onward Therapeutics’s complete investments and acquisitions history, request access »

Onward Therapeutics Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
EMERCell Paris, France 2013

Onward Therapeutics FAQs

  • When was Onward Therapeutics founded?

    Onward Therapeutics was founded in 2019.

  • Where is Onward Therapeutics headquartered?

    Onward Therapeutics is headquartered in Taipei, Taiwan.

  • What is the size of Onward Therapeutics?

    Onward Therapeutics has 13 total employees.

  • What industry is Onward Therapeutics in?

    Onward Therapeutics’s primary industry is Drug Discovery.

  • Is Onward Therapeutics a private or public company?

    Onward Therapeutics is a Private company.

  • What is Onward Therapeutics’s current revenue?

    The current revenue for Onward Therapeutics is .

  • How much funding has Onward Therapeutics raised over time?

    Onward Therapeutics has raised $112M.

  • Who are Onward Therapeutics’s investors?

    Bailey Biofund, Chlitina, Everbright Biofund, Grand Fortune Capital (HK) Company, and Hercules Bioventure Partners Taiwan are 5 of 10 investors who have invested in Onward Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process